Advertisement

Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries

  • Jessica Yasmine Islam
  • Alexis M. Hoyt
  • Silvina Ramos
  • Karen Morgan
  • Chan Joo Kim
  • Sylvia de Sanjose
  • Nicole Butera
  • Virginia Senkomago
  • Karin L. Richter
  • Mary Anne McDonald
  • Nadja A. Vielot
  • Jennifer S. Smith
Original paper

Abstract

Purpose

The World Health Organization revised its human papillomavirus (HPV) vaccination recommendations to include a two (2-) dose schedule for girls aged ≤ 15 years. We investigated acceptability of 2- versus 3-dose schedule among adolescent vaccination providers and mothers of adolescent girls in five countries.

Methods

Adolescent vaccination providers (N = 151) and mothers of adolescent girls aged 9–14 years (N = 118) were recruited from Argentina, Malaysia, South Africa, South Korea, and Spain. We assessed providers’ preference for a 2- versus 3-dose HPV vaccination schedule via quantitative surveys. Mothers’ attitudes towards a 2-dose schedule were assessed through focus group discussions.

Results

Most adolescent providers preferred a 2- over a 3-dose HPV vaccination schedule (overall: 74%), with preference ranging from 45.2% (South Africa) to 90.0% (South Korea). Lower cost, fewer clinic visits, and higher series completion were commonly cited reasons for 2-dose preference among providers and mothers. Safety and efficacy concerns were commonly cited barriers to accepting a 2-dose HPV vaccination schedule among providers and mothers. Mothers generally accepted the reduced schedule, however requested further information from a trusted source.

Conclusions

Adolescent vaccination providers and mothers preferred the 2-dose over 3-dose HPV vaccination schedule. Acceptability of a 2-dose HPV vaccination could be improved with additional information to providers and mothers on HPV vaccination safety and efficacy.

Keywords

Adolescent vaccination Acceptability Human papillomavirus Dose Adolescent Providers Parents Focus groups 

Abbreviations

HIV

Human immunodeficiency virus

HPV

Human  papillomavirus

LMIC

Low- and middle-income country

SAGE

Strategic Advisory Group of Experts

STI

Sexually transmitted infections

WHO

World Health Organization

Notes

Acknowledgments

The authors gratefully acknowledge the participants of this study. The authors thank Suzanne Landi, Shoshana Goldberg, and Sara Smith for their assistance in developing this manuscript. JYI was supported by a NIH NRSA individual predoctoral fellowship (F31-CA210474-01A1). Cervarix is a trademark owned by or licensed to the GSK group of companies.

Funding

This study was funded by GlaxoSmithKline Biologicals SA (Study ID: 117339); all data collection, analysis, and interpretation was conducted by study co-authors, and GSK had the opportunity to review this paper. GSK did not have input into the research data collection, analysis, or interpretation of results.

Compliance with ethical standards

Conflict of interest

Jennifer S. Smith has received research grants, served on paid advisory boards, and/or been a paid speaker for GSK group of companies and Merck & Co., Inc. over the past 5 years. The remaining authors have no conflicts of interest to disclose.

References

  1. 1.
    World Health Organization (2014) Human papillomavirus vaccines: WHO position paper. World Health Organization, GenevaGoogle Scholar
  2. 2.
    World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017. World Health Organization, GenevaGoogle Scholar
  3. 3.
    Clendinen C, Zhang Y, Warburton R, Light D (2016) Manufacturing costs of HPV vaccines for developing countries. Vaccine 34(48):5984–5989CrossRefGoogle Scholar
  4. 4.
    Remes P, Selestine V, Changalucha J, Ross D, Wight D, de Saniose S, Hayes R, Watson-Jones D (2012) A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 30(36):5363–5367CrossRefGoogle Scholar
  5. 5.
    LaMontagne D, Barge S, Le N, Mugisha E, Penny M, Gandhi S, Janmohamed A, Kumakech E, Mosqueira N, Nguyen N, Paul P, Tang Y, Minh T, Uttekar B, Jumaan A (2011) Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 89(11):821–830BCrossRefGoogle Scholar
  6. 6.
    Brewer N, Fazekas K (2007) Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 45(2–3):107–114CrossRefGoogle Scholar
  7. 7.
    Wigle JCE, Watson-Jones D (2013) Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMIC): health system experiences and prospects. Vaccine 31(37):3811–3817CrossRefGoogle Scholar
  8. 8.
    Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M (2014) Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32(6):725–732CrossRefGoogle Scholar
  9. 9.
    Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele D, Kollmann T, Halperin S, Langley J, Bettinger J, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802CrossRefGoogle Scholar
  10. 10.
    Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccine 7(12):1374–1386CrossRefGoogle Scholar
  11. 11.
    Romanowski B, Schwarz T, Ferguson M, Klaus P, Dionne M, Schulze K, Ramjattan B, Hillemanss P, Behre U, Suryakiran P, Thomas F, Struyf F (2014) Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Hum Vaccines Immunother 10(5):1155–1165CrossRefGoogle Scholar
  12. 12.
    Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Behre U, Hillemanns P, Suryakiran P, Thomas F, Struyf F (2016) Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Vaccine 12(1):20–29CrossRefGoogle Scholar
  13. 13.
    World Health Organization (2017) Immunization, vaccines and biologicals: human papillomavirus (HPV). http://www.who.int/immunization/hpv/en/. Accessed July 2018
  14. 14.
    Francis S, Katz M (2013) The HPV vaccine: a comparison of focus groups conducted in South Africa and Ohio Appalachia. Matern Child Health J 17(7):1222–1229CrossRefGoogle Scholar
  15. 15.
    Hertweck S, LaJoie A, Pinto M, Flamini L, Lynch T, Logsdon M (2013) Health care decision making by mothers for their adolescent daughters regarding the quadrivalent HPV vaccine. J Pediatr Adolesc Gynecol 26(2):96–101CrossRefGoogle Scholar
  16. 16.
    Katz I, Nkala B, Dietrich J, Wallace M, Bekker L, Pollenz K, Bogart L, Wright A, Tsai A, Bangsberg D, Gray G (2013) A qualitative analysis of factors influencing HPV vaccine uptake in Soweto, South Africa among adolescents and their caregivers. PLoS ONE 8(8):e72094CrossRefGoogle Scholar
  17. 17.
    Rambout L, Tashkandi M, Hopkins L, Tricco A (2014) Self-reported barriers and facilitators to preventive human papillomavirus vaccination among adolescent girls and young women: a systematic review. Prev Med 58:22–32CrossRefGoogle Scholar
  18. 18.
    Oh J, Lim M, Yun E, Lee E, Shin H (2010) Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey. Vaccine 28(7):1854–1860CrossRefGoogle Scholar
  19. 19.
    Navarro-Illana P, Caballero P, Tuells J, Puig-Barbera J, Diez-Domingo J (2015) Acceptability of human papillomavirus vaccine in mothers from Valencia (Spain). An Pediatr 83(5):318–327CrossRefGoogle Scholar
  20. 20.
    Watson-Jones D, Mugo N, Lee S, Mathai M, Vusha S, Ndirangu G, Ross D (2015) Access and attitudes of HPV vaccination amongst hard-to-reach populations in Jenya. PLoS ONE 10(6):e0123701CrossRefGoogle Scholar
  21. 21.
    Crann S, Barata P, Mitchell R, Mawhinney LT, Chirenje P, Stewart M D (2016) Healthcare providers’ perspectives on the acceptability and uptake of HPV vaccines in Zimbabwe. J Psychosom Obstet Gynecol 37(4):147–155CrossRefGoogle Scholar
  22. 22.
    Hopkins T, Wood N (2013) Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 31(13):1673–1679CrossRefGoogle Scholar
  23. 23.
    Asiedu G, Breitkopf C, Kremers W, Ngo Q, Nguyen N, Barenberg B, Tran V, Dinh T (2015) Vietnamese health care providers’ preferences regarding recommendation of HPV vaccines. Asian Pac J Cancer Prev 16(12):4895–4900CrossRefGoogle Scholar
  24. 24.
    Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S (2014) Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 168(1):76–82.  https://doi.org/10.1001/jamapediatrics.2013.2752 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    McLellan E, MacQueen KM, Neidig JL (2003) Beyond the qualitative interview: data preparation and transcription. Field Methods 15(1):63–84CrossRefGoogle Scholar
  26. 26.
    Vaismoradi M, Turunen H, Bondas T (2013) Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci 15(4):398–405CrossRefGoogle Scholar
  27. 27.
    MacQueen KM, McLellan-Lemal E, Bartholow K, Milstein B (2008) Team-based codebook development: structure, process and agreement. In: Handbook for team-based qualitative research. Altamina Press, Lanham, pp 119–135Google Scholar
  28. 28.
    Bernard HR, Ryan GW (2010) Analyzing qualitative data: systematic approaches. Sage, Thousand OaksGoogle Scholar
  29. 29.
    Guest G, MacQueen KM, Namey EE (2012) applied thematic analysis. Sage, Thousand OaksCrossRefGoogle Scholar
  30. 30.
    Saldana J (2013) The coding manual for qualitative researchers, 3rd edn. Sage, Thousand OaksGoogle Scholar
  31. 31.
    Jit M, Brisson M, Laprise J, Hong Choi Y (2015) Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 350Google Scholar
  32. 32.
    Laprise J, Markowitz L, Chesson H, Drolet M, Brisson M (2016) Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis 214(5):685–688CrossRefGoogle Scholar
  33. 33.
    Laprise J-F, Markowitz LE, Chesson HW, Drolet M, Brisson M (2016) Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. J Infect Dis 214(5):685–688CrossRefGoogle Scholar
  34. 34.
    Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT (2016) Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine 34(9):1187–1192.  https://doi.org/10.1016/j.vaccine.2016.01.023 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Smith P, Stokley S, Bednarczyk R, Orenstein W, Omer S (2016) HPV vaccination coverage of teen girls: the influence of health care providers. Vaccine 18(34):1604–1610CrossRefGoogle Scholar
  36. 36.
    Rahman M, Laz T, McGrath C, Berenson A (2016) Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13- to 17-year-old U.S. adolescent children. Clin Pediatr 54(4):371–375CrossRefGoogle Scholar
  37. 37.
    Allison MA, Hurley LP, Marokwitz L, Crane LA, Brtnikova M, Beaty BL, Snow M, Cory J, Stokley S, Roark J, Kempe A (2016) Primary care physicians’ perspectives about HPV vaccine. Pediatrics 137(2):e20152488CrossRefGoogle Scholar
  38. 38.
    Kulczycki A, Qu H, Shewchuk R (2016) Primary care physicians’ adherence to guidelines and their likelihood to prescribe the human papillomavirus vaccine for 11- and 12-year-old girls. Women’s Health Issues 26(1):34–39CrossRefGoogle Scholar
  39. 39.
    Kyong-No N, Chang K, Cho S, Park S, Park S (2017) Attitudes regarding HPV vaccinations of children among mothers with adolescent daughters in Korea. J Korean Med Sci 32(1):130–134CrossRefGoogle Scholar
  40. 40.
    Vermandere H, Naanyu V, Mabeya H, Broeck D, Michielsen K, Degomme O (2014) Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS ONE 10(3):e0117761Google Scholar
  41. 41.
    Cunningham M, Skrastins E, Fitzpatrick R, Jindal P, Olola O, Yeates K, Booth C, Carpenter J, Aronson K (2015) Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open 5(3):e005828CrossRefGoogle Scholar
  42. 42.
    Jaspers L, Budiningsih S, Wolterbeek R, Henderson F, Peters A (2011) Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: a cross-sectional study. Vaccine 29(44):7785–7793CrossRefGoogle Scholar
  43. 43.
    Cover J, Nghi N, LaMontagne D, Huyen D, Hien N, Nga le T (2012) Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health 12(629):629CrossRefGoogle Scholar
  44. 44.
    Larson H, Jarrett C, Eckersberger E, Smith D, Paterson P (2014) Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine 32(19):2150–2159CrossRefGoogle Scholar
  45. 45.
    Gallagher KE, Howard N, Kabakama S, Mounier-Jack S, Griffiths UK, Feletto M, Burchett HED, LaMontagne DS, Watson-Jones D (2017) Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries. PLoS One.  https://doi.org/10.1371/journal.pone.0177773 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ferrer H, Trotter C, Hickman M, Audrey S (2014) Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health 14:700CrossRefGoogle Scholar
  47. 47.
    Galagan S, Paul P, Menezes L, LaMontagne D (2013) Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine 31(30):3072–3078CrossRefGoogle Scholar
  48. 48.
    Widman C, Rodriguez E, Saad-Harfouche F, Tawrozek A, Erwin D, Mahoney M (2017) Clinician and parent perspectives on educational needs for increasing adolescent HPV vaccination. J Cancer Educ 33:332–339CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Jessica Yasmine Islam
    • 1
  • Alexis M. Hoyt
    • 2
  • Silvina Ramos
    • 3
  • Karen Morgan
    • 4
    • 5
  • Chan Joo Kim
    • 6
  • Sylvia de Sanjose
    • 7
  • Nicole Butera
    • 8
  • Virginia Senkomago
    • 2
  • Karin L. Richter
    • 9
  • Mary Anne McDonald
    • 10
  • Nadja A. Vielot
    • 11
  • Jennifer S. Smith
    • 2
    • 12
    • 13
  1. 1.Department of Epidemiology, Gillings School of Global Public HealthUniversity of North CarolinaChapel HillUSA
  2. 2.Department of Health Behavior, Gillings School of Global Public HealthUniversity of North CarolinaChapel HillUSA
  3. 3.Centro de Estudios de Estado y SociedadBuenos AiresArgentina
  4. 4.Perdana University School of MedicineSeri KembanganMalaysia
  5. 5.Royal College of SurgeonsDublinIreland
  6. 6.Department of Obstetrics and Gynecology, The Catholic University of Korea College of MedicineSt. Paul’s HospitalSeoulSouth Korea
  7. 7.Infections and Cancer, Cancer Epidemiology Research ProgrammeInstitut Català d’OncologiaBarcelonaSpain
  8. 8.Department of Biostatistics, Gillings School of Global Public HealthUniversity of North CarolinaChapel HillUSA
  9. 9.Department of Medical Virology, University of PretoriaNational Health Laboratory ServicePretoriaSouth Africa
  10. 10.Center on Genomics, Race, Identity, DifferenceDuke UniversityDurhamUSA
  11. 11.Department of Family Medicine, School of MedicineUniversity of North CarolinaChapel HillUSA
  12. 12.UNC Lineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel HillUSA
  13. 13.Department of EpidemiologyUNC Gillings School of Global Public HealthChapel HillUSA

Personalised recommendations